Hemolytic-Uremic Syndrome: A High-Yield USMLE Review
Hemolytic-uremic syndrome is a toxin-mediated disease characterized by the triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury. It classically follows enterohemorrhagic E. coli (EHEC, O157:H7) enterocolitis and is a favorite USMLE example of how giving the 'obvious' treatment — antibiotics — makes the patient worse. Recognizing HUS and withholding antibiotics is the tested point.
Pathophysiology
EHEC (E. coli O157:H7) produces a Shiga-like toxin. The toxin damages endothelium and drives a microangiopathic process that mechanically shears red cells (producing schistocytes and hemolytic anemia), consumes platelets (thrombocytopenia), and injures the kidney (acute kidney injury). Critically, bactericidal antibiotics that lyse the organism release preformed toxin into the gut lumen and upregulate toxin gene expression in stressed bacteria — both amplify toxin delivery and push the patient toward worsening HUS.
Presentation
- Preceding bloody diarrhea, fever, and abdominal pain, classically in a young child with E. coli O157:H7 enterocolitis
- Microangiopathic hemolytic anemia — severe anemia with schistocytes on peripheral smear
- Thrombocytopenia — low platelet count
- Acute kidney injury — rising creatinine, progressing toward renal failure
Diagnosis
- Peripheral blood smear showing schistocytes, confirming microangiopathic hemolysis
- Complete blood count and chemistries showing anemia (e.g., hemoglobin ~7 g/dL), thrombocytopenia (e.g., platelets ~45,000), and elevated creatinine (e.g., 3.2 mg/dL)
- Stool studies identifying E. coli O157:H7 as the causative organism
Management
- Supportive care is the standard of care: fluid resuscitation, blood transfusion for severe anemia, and dialysis if renal failure progresses
- Platelet transfusion only for active bleeding
- Do NOT give antibiotics — bactericidal agents increase toxin release and worsen HUS
- Avoid antimotility agents, which can worsen toxin retention
High-yield
- Classic triad: microangiopathic hemolytic anemia + thrombocytopenia + acute kidney injury
- Caused by Shiga-like toxin from E. coli O157:H7 (EHEC)
- Schistocytes on peripheral smear are the hallmark of the microangiopathic hemolysis
- The canonical 'mechanism-predicts-the-therapy-is-wrong' case: antibiotics are contraindicated because killing the source amplifies the toxin
Pitfalls
- Reflexively treating the bloody diarrhea as bacterial enteritis and starting antibiotics (e.g., ciprofloxacin or a beta-lactam) — this increases toxin release and worsens HUS
- Giving antimotility agents, which promote toxin retention
- Giving prophylactic platelet transfusions in the absence of active bleeding rather than reserving them for bleeding
Don't just memorize Hemolytic-Uremic Syndrome (HUS) — practice reasoning through it on branching cases where your decisions shape the patient.